First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Thrombosis and Thrombolysis"
DOI: 10.1007/s11239-018-1709-z
Abstract: Rivaroxaban and apixaban are direct oral anticoagulants whose target specificity is to activate factor X (FXa). It is still not fully understood how xabans impact platelet function. This single-center observational study aimed to assess in… read more here.
Keywords: platelet aggregation; rivaroxaban apixaban; platelet; first evidence ... See more keywords
International Normalized Ratio Is Significantly Elevated With Rivaroxaban and Apixaban Drug Therapies: A Retrospective Study.
Sign Up to like & getrecommendations! Published in 2017 at "Clinical therapeutics"
DOI: 10.1016/j.clinthera.2017.04.007
Abstract: PURPOSE Direct factor Xa inhibitors such as rivaroxaban or apixaban may prolong prothrombin time (PT) and elevate international normalized ratio (INR). However, these tests are not reliable for assessing the anticoagulation effects of these agents.… read more here.
Keywords: inr; rivaroxaban apixaban; international normalized; study ... See more keywords
Comparison of peri-procedural anticoagulation with rivaroxaban and apixaban during radiofrequency ablation of atrial fibrillation
Sign Up to like & getrecommendations! Published in 2020 at "Indian Pacing and Electrophysiology Journal"
DOI: 10.1016/j.ipej.2020.08.002
Abstract: Introduction Prospective studies on rivaroxaban and apixaban have shown the safety and efficacy of direct anticoagulation agents (DOAC)s used peri-procedurally during radiofrequency ablation (RFA) of atrial fibrillation (AF). Studies comparing the two agents have not… read more here.
Keywords: atrial fibrillation; anticoagulation; rivaroxaban; rivaroxaban apixaban ... See more keywords
Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.
Sign Up to like & getrecommendations! Published in 2017 at "Thrombosis research"
DOI: 10.1016/j.thromres.2017.09.001
Abstract: Dabigatran etexilate, rivaroxaban and apixaban (DOACs) are widely used and measurement of their concentration is desirable in certain clinical situations. Target-specific assays are available but limited information exists on their performance especially in their ability… read more here.
Keywords: multicenter; dabigatran rivaroxaban; target specific; rivaroxaban apixaban ... See more keywords
Assessment of DOAC in GEriatrics ( Adage Study): Rivaroxaban/Apixaban Concentrations and Thrombin Generation Profiles in NVAF Very Elderly Patients
Sign Up to like & getrecommendations! Published in 2022 at "Thrombosis and Haemostasis"
DOI: 10.1055/a-1981-1763
Abstract: Background Although a growing number of very elderly patients with atrial fibrillation (AF), multiple conditions, and polypharmacy receive direct oral anticoagulants (DOACs), few studies specifically investigated both apixaban/rivaroxaban pharmacokinetics and pharmacodynamics in such patients. Aims… read more here.
Keywords: thrombin generation; rivaroxaban apixaban; elderly patients; adage ... See more keywords
Stability of Rivaroxaban and Apixaban Anti-Xa Activities in Whole Blood Samples: A French Bicentric Study
Sign Up to like & getrecommendations! Published in 2023 at "Thrombosis and Haemostasis"
DOI: 10.1055/s-0043-1763254
Abstract: Over the last 10 years, the use of direct oral anticoagulants (DOACs) in the management of venous thromboembolism and atrial fi brillation grew signi fi cantly, and in particular direct factor Xa inhibitors rivaroxaban and… read more here.
Keywords: rivaroxaban apixaban; blood samples; whole blood; stability ... See more keywords
Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Internal Medicine"
DOI: 10.1111/joim.12683
Abstract: Comparative data of non‐vitamin K antagonist oral anticoagulants (NOAC) are lacking in patients with atrial fibrillation (AF). read more here.
Keywords: atrial fibrillation; standard reduced; rivaroxaban apixaban; doses dabigatran ... See more keywords
Comparative effectiveness and safety of edoxaban, rivaroxaban, and apixaban in patients with venous thromboembolism: A cohort study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.15799
Abstract: Although several studies have compared the effectiveness and safety of rivaroxaban and apixaban in patients with venous thromboembolism (VTE), direct comparison of these drugs with edoxaban is lacking. read more here.
Keywords: rivaroxaban apixaban; patients venous; apixaban patients; venous thromboembolism ... See more keywords
Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies
Sign Up to like & getrecommendations! Published in 2022 at "Cardiovascular Therapeutics"
DOI: 10.1155/2022/2756682
Abstract: Background Rivaroxaban and apixaban are the most widely used nonvitamin K oral anticoagulants (NOACs) in patients with venous thromboembolism (VTE). This meta-analysis evaluates the effectiveness and safety of both NOACs versus standard of care (SoC)… read more here.
Keywords: meta analysis; rivaroxaban apixaban; real world;
The Impact of Rivaroxaban and Apixaban on Tacrolimus Trough Levels
Sign Up to like & getrecommendations! Published in 2021 at "Progress in Transplantation"
DOI: 10.1177/15269248211024601
Abstract: The solid organ transplant community is slow to adopt the routine practice of using direct oral anticoagulants. Rivaroxaban and apixaban share common metabolic pathways with tacrolimus. This study aimed to clarify the impact of rivaroxaban/apixaban… read more here.
Keywords: tacrolimus troughs; rivaroxaban apixaban; impact rivaroxaban; apixaban ... See more keywords
Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study.
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood-2017-05-782060
Abstract: There is uncertainty regarding the effectiveness and occurrence of thromboembolic events in patients treated with prothrombin complex concentrates (PCCs) for the management of major bleeding events (MBEs) on rivaroxaban or apixaban. We investigated the effectiveness… read more here.
Keywords: rivaroxaban apixaban; major bleeding; management; pccs ... See more keywords